Evaluation of antiviral activity of *Bacillus licheniformis*-fermented products against porcine epidemic diarrhea virus

Ju-Yi Peng1,2†, Yi-Bing Horng3†, Ching-Ho Wu2,4, Chia-Yu Chang1,2†, Yen-Chen Chang1,2, Pei-Shiue Tsai2, Chian-Ren Jeng1,2, Yeong-Hsiang Cheng3* and Hui-Wen Chang1,2*

Abstract

*Bacillus licheniformis* (*B. licheniformis*) is commonly used as probiotic and its secondary metabolites are attractive anti-microbial candidate. In the present study, we aimed to evaluate the antiviral activity of crude extracts from *B. licheniformis* against porcine epidemic diarrhea virus (PEDV), a highly contagious enveloped porcine virus that has caused great economic loss in pigs. In vivo, PEDV-infected piglets supplemented with air-dried solid state fermentative cultivate containing *B. licheniformis*-fermented products (BLFP) showed milder clinical symptoms and decreased viral shedding. Importantly, no significant systemic pathological lesions and no reduction in average daily gain were noted in pigs supplemented with the BLFP, which suggests that it is safe for use in pigs. In vitro experiments revealed that while *B. licheniformis* crude extracts exhibited no toxicity in Vero cells, co-cultivation of *B. licheniformis* crude extracts with PEDV significantly reduced viral infection and replication. Summarized current results suggest that the *B. licheniformis*-fermented products could be a novel candidate food additive for reducing the impact of PED on the swine industry.

Keywords: *B. licheniformis*-fermented products, PEDV, Antiviral

Introduction

Beginning in 2013, outbreaks of new variants of porcine epidemic diarrhea virus (PEDV) have caused high mortality and morbidity in piglets, leading to great economic losses (Lee 2015). The virus causes porcine epidemic diarrhea (PED), which is characterized by watery diarrhea, vomiting, and severe dehydration in pigs of all ages, especially suckling piglets (Lee 2015; Song and Park 2012). This highly contagious disease has spread quickly in porcine industries in several countries (Jung and Saif 2015; Lee 2015). Furthermore, PEDV infection causes severe perturbations of gut microbiota, reducing probiotic bacterial abundance, enriching pathogenic bacteria, and even impairing the growth performance of PEDV-surviving pigs (Alvarez et al. 2015; Deping Song et al. 2017). The development of effective protective agents against PEDV infection is urgently needed.

Probiotics is one of the choices to be an alternative to antibiotic growth promoter, AGP (Abudabos et al. 2017). Our recent studies reported that *Lactobacillus* species and *Clostridium butyricum*-fermented probiotics product alleviate diarrhea incidence and reduce the gut pathogens in weaning piglets (Cheng et al. 2019). On the other hand, *Bacillus subtilis* (*B. subtilis*) and *B. licheniformis*–fermented products could increase growth performance and mitigate *Clostridium perfringens*–induced necrotic enteritis in broilers (Cheng et al. 2018; Lin et al. 2019). Enhancement of nutrient digestibility and *Lactobacillus* counts of feces by feeding *B. subtilis* and *B. licheniformis* has also been reported in pigs (Lan and Kim 2019). It
has been demonstrated that *B. licheniformis* exhibiting antimicrobial activity against pathogens might be due to the production of antibacterial biosurfactants (Lin et al. 2019). Furthermore, our experiment results also demonstrated that *B. licheniformis*-fermented products exhibit antibacterial activities against *Clostridium perfringens* and *Staphylococcus aureus* in vitro (Lin et al. 2019).

In the present study, the antiviral effect of the BLFP crude extract against PEDV were evaluated in pigs. The surfactin-like peptide in the BLFP crude extract was identified from the secondary metabolite of *B. licheniformis* fermentative cultivates. The in vitro toxicity and antiviral ability of the surfactin-like peptide in the BLFP crude extract against PEDV were evaluated using the Vero cells.

### Materials and methods

#### Cells and viruses

Vero C1008 cells (American Type Culture Collection (ATCC) No. CRL-1586) were maintained in DMEM (Gibco, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, Utah, USA) and 1% penicillin–streptomycin–amphotericin B (Gibco, NY, USA). The passage 6 PEDV-Pintung 52 strain (PEDVPT-P6) viral stock was used at a titer of 1 × 10^5 TCID\textsubscript{50}/mL.

#### Extraction and quantification of biosurfactants from BLFP crude extract

Air-dried solid-state fermentative cultivates of *B. licheniformis* (Weigmann) Chester (ATCC\textsuperscript{®}27811\textsuperscript{™}) were suspended in distilled water and heated at 30 °C for 30 min. Supernatants were harvested after centrifugation at 13,000 rpm for 30 min. After adjusting the pH value to 2.0 with 6 N HCl for protein precipitation, the precipitates were dried in a freeze dryer after washing twice with distilled water. This *B. licheniformis*-fermented products (BLFP) was used in animal study. To characterized the BLFP, the surfactin derived from *Bacillus subtilis* (Sigma-Aldrich, St Louis, USA) was used as standard substance. The content of BLFP in the fermentative product was determined by high-performance liquid chromatography (HPLC) as previously described (Schneider and Marathiel 1998). Briefly, after filtration, samples were subjected to analysis via SPD-10A HPLC (Shimadzu, Tokyo, Japan) with a pre-packed LiChrospher 100 RP-18 column (Merck, Darmstadt, Germany). The mobile phase was a mixture of 3.8 mM trifluoroacetic acid and 200 ml DDW with 800 ml 100% methanol. Elution was performed at a flow rate of 1 ml/min and determined with a UV detector (10A VP, Shimadzu, Tokyo, Japan) at 210 nm. The gradient strategy was as follows: 0–3.5 min, 60% A to 93% A; 3.5–20 min, keeping 93% A and 7% B (A, acetonitrile; B, ultrapure water); min pressure 0 bar, max pressure 400 bar, pressure stability 10 bar; injection volume 10 μl; syringe speed 8 μl/s; flush volume 800 μl. Liquid chromatography–mass spectrometry (LC–MS) full scan positive mode was performed with m/z ranging from 200 to 2000.

#### Animals and study design

Fifteen 4-week-old, PEDV-fecal RNA and PEDV seronegative, Large White × Duroc crossbred pigs were acquired from a conventional pig farm with no known history of PED. Treatments were: (1) Control (n=5); (2) PEDV (n=5); and (3) PEDV + BLFP (n=5). These pigs were fed a commercial diet mixed with or without 5 kg/L BLFP as feed additives for 7 days prior to the viral challenge, and were challenged with or without 5 × 10^5 TCID\textsubscript{50} of the virulent PEDVPT-P6 (P6) at 5 weeks of age (Table 1). Each group was housed in a separate fenced area. Clinical symptoms, fecal consistency scoring, and fecal viral shedding were recorded and tested daily. The clinical scores were recorded using a 4-scale: 0, normal feces; 1, pasty; 2, semi-fluid; 3, fluid. All piglets were weighed weekly and sacrificed 19 days post-infection (DPI) for safety assessment by pathological examination. The animal experiment was approved by the Institutional Animal Care and Use Committee of National Taiwan University (Taipei, Taiwan, NTU105-EL-00087).

#### Real-time quantitative RT-PCR

Real-time quantitative RT-PCR (qPCR) was performed based on a previously described method with modification (Chang et al. 2017). The viral RNA was extracted from 200 μl of culture supernatants using Cador® Pathogen 96 QIAcube® (Qiagen, Chatsworth, CA, USA) according to the manufacturer’s instructions. Reverse transcription was performed using the QuantNiova Reverse Transcription Kit (Qiagen) according to the manufacturer’s protocol. For qPCR assay, the QuantNiova Probe Master Mix (Qiagen, Chatsworth, CA, USA) was used with the following primers and probe for PEDV detection: PEDV FN: 5′-CGCAAGACTGAACCCACTAA C-3′; PEDV RN: 5′-TTGCCCTGTGGTTACTTTGAGAT-3′; and probe: 5′-FAM-TGGYACCAYACCACGACTTTG-BHQ1. qPCR was performed under following conditions: 95 °C for 2 min, then 45 cycles of 95 °C for 15 s and 55 °C for 15 s. The averaged cycle threshold (Ct) values of three replicates of extracellular supernatants and five replicates

#### Table 1 Animal experimental design

| Group          | Number | BLFP | Virus challenge |
|----------------|--------|------|-----------------|
| Control        | 5      | 0    | 0               |
| PEDV + BLFP    | 5      | 5 kg/ton feed | PEDVPT-P6 (oral 5 × 10^5 TCID\textsubscript{50}) |
| PEDV           | 5      | 0    | PEDVPT-P6 (oral 5 × 10^5 TCID\textsubscript{50}) |

BLFP, *Bacillus licheniformis*-fermented products
of fecal swabs were used to determine the genomic equivalents (GE). The detection limit of the real-time RT-PCR was 60 GE of DNA using the plasmid encoding the PEDV N gene as a standard (data not shown).

**Gross and histopathological examination**

All pigs were euthanized and necropsy was performed at 19 DPI to evaluate the safety of BLFP in pigs. Representative tissue samples were collected, fixed in 10% neutral-buffered formalin, processed routinely, sliced into 5-μm-thick sections, and stained with hematoxylin and eosin. The histopathological observations were recorded and assessed blindly by one veterinary pathologist.

**In vitro cytotoxicity assay of BLFP crude extract**

To evaluate the cytotoxicity of BLFP crude extract in vitro, Vero cells were first grown in a 96-well microplate (Corning Life Sciences, Corning, NY, USA) at a density of 20,000 cells per well 1 day prior to the experiment. After removing the culture supernatant, ten-fold serially diluted BLFP crude extract in PI medium (DMEM supplemented with 0.3% tryptose phosphate broth (Sigma-Aldrich, Mo, USA), 0.02% yeast extract (Acumedia, Michigan, USA), and 10 μg/ml of trypsin (Sigma-Aldrich, Mo, USA) was added to the cell monolayer. After 48 h, the culture supernatant was removed and 100 μl AlamarBlue™ was added (G-Biosciences, St. Louis, USA; 10% in PBS). After 2 h of incubation at 37 °C, the plate was read with the excitation wavelength at 575 nm and with the emission wavelength at 590 nm. The OD value of each well was calculated to obtain the percentage reduction of alamarBlue according to the manufacturer’s instructions. Additionally, an untreated group G1, which consisted of Vero cells without any treatment, was included to represent 100% reduction of alamarBlue. All data were further calculated as a percentage of the untreated group G1. Normalized data were plotted against concentrations of BLFP crude extract and fitted to a non-linear regression curve using GraphPad Prism (GraphPad Software, San Diego, CA). The 50% cytotoxicity concentration (CC50, the concentration of BLFP at which cellular viability was reduced to 50%) was calculated accordingly.

**Time-of-addition assay of BLFP crude extract**

To study the antiviral activity of BLFP crude extract against PEDV, the biosurfactants were added at different time points during the viral infection. Vero cells were seeded in a 96-well microplate (20,000 cells/well) 1 day before the experiment. BLFP crude extract at 150 ppm in PI medium were added to each well in different orders to treat 200 TCID_{50}/ml PEDV infections in cells. The experiment included five groups (as illustrated in Fig. 4a): the virus treated group (G2) contained Vero cells treated with the solvent of BLFP crude extract; the pre-treatment group (G3) contained Vero cells treated with the BLFP crude extract 1 h prior to PEDV infection; the co-treatment group (G4) contained Vero cells treated with BLFP crude extract at the same time as PEDV infection; the post-treatment group (G5) contained Vero cells treated with BLFP crude extract 1 h post PEDV infection. In G2-G5, culture supernatants were removed and replaced with fresh PI medium after 1 h of viral infection or BLFP crude extract treatment. In addition, the post-drug group (G6) contained Vero cells treated with BLFP crude extract 1 h post PEDV infection and kept in the culture medium for the entire 48 h of the study. After 48 h, the supernatants of all groups were harvested to determine the virus titer and viral load, and cellular viability was examined using the AlamarBlue™ assay as described above.

**Replication kinetics assay of PEDV in cells with or without BLFP crude extract**

To further investigate the antiviral mechanism in the post-drug group (G6), the replication kinetics of PEDV in Vero cells with or without crude extract of BLFP were compared. Vero cells were seeded in a 96-well microplate (20,000 cells/well) 1 day before the experiment. The crude extract of BLFP at 150 ppm in PI medium was added to 200 TCID_{50}/ml PEDV-infected cells. Culture supernatants and cells were collected separately at the 2, 8, 12, 24, and 48 h post-infection. Viral titers in culture supernatants were determined using the Reed-Müench method (Reed 1938) and are expressed as the 50% TCID_{50}/ml. Virus-specific RNA in culture supernatants and in cells was quantified by real-time reverse transcription-PCR.

**Determination of PEDV TCID_{50}**

Virus titration was performed in the culture supernatants. Briefly, the first 10-fold dilution and the subsequent 10-fold serial dilution of the supernatants were added to 20,000 cells/well Vero cells on 96-well microplates. After 1 h of incubation, the inoculants were aspirated, and the cells were washed with PI medium two times and then cultured in PI medium. After 72 h, the plate was subjected to cytopathic effect (CPE) observation and the titer of PEDV was determined using the Reed-Müench method (Reed 1938) and is expressed as the 50% TCID_{50}/ml.

**Determination of IC_{50} of the BLFP crude extract**

To determine the IC_{50}, Vero cells were seeded in 96-well microplates (20,000 cells/well) one day before the experiment. Ten-fold serially diluted crude extract of BLFP in PI medium was added to Vero cells 1 h after 200 50% tissue culture infectious dose (TCID_{50}) PEDV infection. After 48 h, the percent reduction of alamarBluestaining was examined by the AlamarBlue™ assay as described above.
All normalized data were plotted and fitted to a nonlinear regression curve in GraphPad Prism (GraphPad Software) to generate the IC\textsubscript{50}.

**Direct virucidal activity of BLFP crude extract**

To elucidate the direct virucidal activity of crude extract of BLFP against PEDV, the PEDVPT-P6 viral stock at a titer of $1 \times 10^5$ TCID\textsubscript{50}/ml was mixed with or without 150 ppm BLFP for 1 h at 4 °C. The mixtures were serially diluted 10-fold in PI medium and added to Vero cells. After 72 h, the viral titers were determined as described above.

**Statistical analysis**

All data were analyzed and plotted using GraphPad Prism (GraphPad Software). All error bars represent standard deviation (SD). The significance of the differences among groups in the cell-based study was determined using Student’s t test or one-way ANOVA with Tukey’s multiple comparison. A $p$-value of $< 0.05$ was interpreted as statistically significant. The results of the average daily gain (ADG) and fecal RNA shedding in the animal experiments were analyzed and the variables among groups were compared using a non-parametrical Kruskal–Wallis Test, with $p<0.05$ considered significant. All data were analyzed using GraphPad Prism software (GraphPad Prism Inc.).

**Results**

**Extraction and quantification of B. licheniformis-fermented products (BLFP) crude extract**

As shown in Fig. 1, HPLC analysis of the B. licheniformis extract showed a single peak (Fig. 1b) at the retention time of 16–17 min, which is identical to the standard substance surfactin derived from Bacillus subtilis (Fig. 1a).

**Fig. 1** Identification of the 2nd metabolites in standard substance surfactin derived from Bacillus subtilis (a) and fermentative sample derived from Bacillus licheniformis-fermented products (BLFP) (b) by liquid chromatography–mass spectrometry (LC–MS). Using the standard curve of surfactin derived from Bacillus subtilis (c), the 2nd metabolite at $[\text{M}+\text{Na}]^+$ m/z 1058 in Bacillus licheniformis-fermented products crude extract (d) was identified and quantified.
LC–MS analysis revealed that the 2nd metabolites derived from *B. licheniformis* fermentative cultivates appeared at [M+Na]⁺ m/z 1058.35, suggesting a molecular weight of 1036 Dalton (Da) (Fig. 1).

**Clinical scoring of fecal consistency**

To assess the efficacy of the antiviral ability of BLFP against PEDV, clinical symptoms after viral challenge were recorded daily (Fig. 2). The fecal conditions of pigs in all groups were scored as normal (Score = 0) before PEDV inoculation. In general, pigs supplemented with BLFP exhibited milder symptom compared to piglets supplemented with controls. In the control group, all five pigs (5/5) exhibited normal clinical signs (Score = 0) during the study. In the PEDV group in which pigs were supplemented with control food, different severities of PEDV-associated clinical signs were first detected 2 days post infection (DPI). Two of these five pigs (2/5) exhibited semi-fluid feces (Score = 2) at 2 DPI, while 3/5 pigs showed typical semi-fluid (Score = 2) to watery diarrhea (Score = 3) at 2 to 8 DPI, and eventually recovered after 8 DPI. In the PEDV + BLFP group, most of the pigs exhibited pasty feces (Score = 1) at 2–5 DPI. Only one pig exhibited transient typical watery diarrhea (Score = 3) at 6 DPI. Compared to the PEDV-infected group with control food, the severity and duration of typical diarrhea (scores 2–3) were reduced in the PEDV + BLFP group.

**Fecal PEDV viral RNA**

To quantify PEDV-associated fecal viral shedding to evaluate the antiviral efficacy of BLFP against PEDV, RT-qPCR was used to detect fecal viral shedding. In the PEDV group (the grey line in Fig. 3), fecal viral shedding was first detected (3.92 ± 3.88 log_{10}GE) at 2 DPI, found to gradually increase to peak viral load (5.71 ± 3.38 log_{10}GE) at 5 DPI, and was continuously detected until 12 DPI. In the PEDV + BLFP group (the black line in Fig. 3), the pattern of viral shedding was similar to but lower than that in the PEDV group during the study, although the difference was not statistically significant.

**Growth performance of pigs supplemented with BLFP**

All pigs were weighed weekly in order to evaluate their growth performance with and without biosurfactants as a feed additive. No significant difference in the average daily gain (ADG) of pigs was noted among all groups in each week (Fig. 4).

---

**Fig. 2** Clinical scoring of fecal consistency. Compared to PEDV-infected groups, the appearance and duration of typical diarrhea (score 2–3) were reduced in the PEDV + BLFP group.
Gross and histopathological evaluation
To evaluate the safety of BLFP as a feed additive for pigs, necropsy was performed in all piglets 3 weeks post-infection for gross and histopathological examination. For the gross and histopathological examinations, no macroscopic or microscopic lesions were noted in any of the groups. These findings suggest that BLFP as a feed additives at 5 kg/ton are safe in conventional pigs up to 26 days of feeding.

The median cytotoxic concentration (CC$_{50}$) of BLFP crude extract on Vero cells
To determine the median cytotoxic concentration (CC$_{50}$) of BLFP crude extract in Vero cells, the BLFP crude extract was serially diluted 10-fold from 150 to 0.015 ppm and added to cells. 48 h post-incubation (HPI), no cytotoxicity due to BLFP crude extract was observed in Vero cells (Fig. 5).

Maximal inhibitory concentration (IC$_{50}$) determination
To determine the maximal inhibitory concentration, the post-drug group G6 was used to evaluate the maximal inhibitory effect of BLFP crude extract by cocultivating

---

**Fig. 3** Fecal shedding of PEDV-P6 detected in piglets fed < 5 kg/ton BLFP in each group (n = 5). The pattern of viral shedding in the PEDV+BLFP group was similar to but lower than that of the PEDV group during the study, with no significant difference detected. Changes in the mean values of genomic equivalents (GE)/mL are presented as log10 values ± SD. The viral RNA loads of inoculated groups and the control group were compared using a non-parametrical Kruskal–Wallis test

**Fig. 4** Average daily gain of pigs in each group. All pigs were weighed weekly in order to evaluate their growth performance with or without BLFP as feed additives. No statistically significant difference in the average daily gain was noted among all groups each week.
BLFP crude extract with PEDV-infected cells during the whole study. The results indicated that the antiviral activity of BLFP crude extract is dose-dependent, and the inhibition of PEDV-induced CPE was calculated with an IC₅₀ value of 0.07 ± 0.45 ppm (Fig. 6).

**Time-of-addition assay of the BLFP crude extract and dose-dependent inhibition**

To elucidate the antiviral activity of BLFP crude extract against PEDV, 150 ppm of BLFP crude extract was added to the culture at different time points during the viral infection. As shown in Fig. 6a, typical PEDV-induced CPE was characterized by formation of syncytial cells, cell death, and detachment from the culture plate in PEDV-infected cells. The percent reductions of AlamarBlue™ staining in G3–G5—cells treated with BLFP crude extract 1 h before infection, at the same time as infection, and 1 h after viral infection, then replaced with fresh PI medium—were calculated as 50.7 ± 16.2%, 26.0 ± 20.1%, and 44.3 ± 5.8%, respectively, and showed no significant...
differences from those in the PEDV-infected group G2 (Fig. 7b). For the post-drug group G6, significant inhibition of PEDV-induced CPE, with an 81.5 ± 7.61% reduction of AlamarBlue staining, was observed compared to that in G2 and other groups (G3–G5). Similarly, the amount of viral RNA in supernatants from G6, ranging from 6.26 to 7.39 log₁₀ GE, was significantly lower than that of G2–G5, ranging from 8.41 to 9.26 log₁₀ GE (Fig. 7c). Additionally, the viral titer of supernatants in the G6 group, which was less than 10⁴ TCID₅₀/ml, was lower than that of G2–G5, ranging from 1 × 10⁴ to 1 × 10⁵ TCID₅₀/ml. Moreover, when evaluating the direct virucidal activity of BLFP crude extract against PEDV, a reduction of the viral titer of PEDV from 10⁵ to 10⁴ TCID₅₀/ml was observed.

Replication kinetics of PEDV in cells with or without BLFP crude extract

To further investigate the antiviral mechanism in the post-drug group (G6), the replication kinetics of PEDV in Vero cells in the presence or absence of BLFP crude extract were determined. Compare to PEDV-infected Vero cells cultured without BLFP crude extract, which showed viral titers from 1.78 × 10⁵ at 24 HPI to 3.16 × 10⁶ TCID₅₀/ml at 48 HPI (Fig. 8a), cells treated with BLFP crude extract had an undetectable extracellular viral titer, which was significantly lower than that of cells without BLFP crude extract. Similarly, extracellular viral RNA levels in PEDV-infected cells cultured with biosurfactants were significantly lower than those without BLFP crude extract 24 and 48 HPI (Fig. 8b). However, no significant differences in intracellular viral titers (Fig. 8c) or intracellular viral RNA (Fig. 5d) were noted in PEDV-infected cells treated with or without BLFP crude extract.

Discussion

Since late 2013, new variants of PEDV have been identified in several counties and have caused a devastating disease and economic loss. This viral threat has prompted a global effort to develop antivirals against new variant PEDVs in vitro (Song and Choi 2011; Kwon et al. 2013) and in vivo (Cho et al. 2012; Kim et al. 2015). Herein, we demonstrated that: (1) BLFP crude extract presents no cell toxicity to Vero cells, and exhibits significant antiviral ability against PEDV-P6 in Vero cells when biosurfactants are co-cultivated with PEDV; (2) Piglets supplemented with BLFP at concentrations of 5 kg/ton or less exhibited milder clinical symptoms and lower viral shedding compared to piglets supplemented with control food, and BLFP caused no significant toxicity. Therefore, BLFP is suggested to be a promising novel feed additive that can act as an additive against PEDV in the field.

The main antiviral mechanism of BLFP crude extract is thought to be related to its unique biochemical structure that increases membrane permeability to disrupt and lyse microbial membranes (Huang et al. 2006). By
performing a direct-virucidal study of BLFP crude extract against PEDV, a ten-fold reduction of the viral titer was able to confirm the directed-antiviral ability of BLFP crude extract. According to our HPLC analysis, a peak of surfactin-like peptide was identified in the BLFP crude extract. Several different potential antiviral mechanisms of biosurfactants have been previously reported (Vollenbroich et al. 1997; Wang et al. 2017). Lipopeptide biosurfactants have been previously suggested to possess probiotic attributes for animal and human use (Schneider 1998; Sen 2010). A previous study demonstrated that the antiviral ability of surfactin from \textit{B. subtilis} was achieved through competition with the TGEV entry receptor (Wang et al. 2017). The inhibition of viral enzymes such as proton-ATPase that are required for the entry of some viruses into cells by surfactin from \textit{B. subtilis} (Vollenbroich et al. 1997) has also been reported. It is worth noting that not only did co-cultivation of the surfactin-like peptide in the BLFP crude extract with PEDV-infected Vero cells significantly reduce viral infection and replication in the study, but BLFP crude extract-treated PEDV-infected cells also exhibited an undetectable extracellular viral titer, suggesting that BLFP crude extract may play an important role in reducing the release of virions. These results suggest additional mechanisms of BLFP crude extract against PEDV in Vero cells. Although further study of the antiviral mechanisms of BLFP crude extract is needed in the future, observation of the diverse antiviral activities of BLFP crude extract will lead to further development of this new therapeutic candidate.

Previous studies demonstrated that lipopeptides produced by various \textit{Bacillus} spp. were safe in mice (Youn-Hwan Hwang et al. 2008) and weaned piglets (Torres et al. 2017) when administered under certain concentration. In order to use BLFP as a feed additive for its antiviral properties, assessment of its antiviral and safety profile in pigs is essential. Our results demonstrated that piglets supplemented with BLFP show milder symptoms.
and have reduced viral shedding. Importantly, no significant systemic pathological effects and no changes in average daily gain were noted. These results suggest that the biosurfactants at concentrations of 5 kg/ton or less will be very safe in pigs in future applications. In a previous study, it was found that administration of surfactin from B. subtilis at over 500 kg/ton leads to necrosis of hepatocytes in rats (Hwang et al. 2009). In the future, animal experiments using higher dosages of biosurfactants would be necessary to validate its maximal safety dosage.

In the present study, BLFP was investigated as an antiviral candidate against PEDV. In vitro, BLFP crude extract exhibited antiviral activities against PEDV when incubated long-term with PEDV-infected cells. In vivo, we first validated the safety and antiviral ability against of BLFP as a feed additive less than 5 kg/ton against PEDV after a long period of PEDV inoculation. Our results suggest that BLFP could be a novel candidate feed additive for reducing the titer of PEDV in the swine industry.

Authors’ contributions
J-YP, Y-BH, and C-YC have drafted, revised the work, conducted the experiments; Y-BH and Y-HC provided specimens and substantial contributions to the conception and analysis; H-WC, Y-CC, P-ST, and C-RJ help to interpret data; Y-HC and H-WC designed the work and approve the submitted version. All authors read and approved the final manuscript.

Funding
This work was supported by the Ministry of Science and Technology, Taiwan, Republic of China (R.O.C.) for grants MOST 107-2321-B-197-002-, MOST 108-2321-B-197-001, and 108L7842 from National Taiwan University, Taiwan, R.O.C.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087). The animal experiment was approved by the Institutional Animal Care and Use Committee (IACUC) of National Taiwan University (Taipei, Taiwan, NTU105‑EL‑00087).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Graduate Institute of Molecular and Comparative Pathobiology, School of Veterinary Medicine, National Taiwan University, No. 1, Section 4, Roosevelt Rd., Taipei 10617, Taiwan. 2 School of Veterinary Medicine, National Taiwan University, No. 1, Section 4, Roosevelt Rd., Taipei 10617, Taiwan. 3 Department of Biotechnology and Animal Science, National Ilan University, No. 1, Sec. 1, Shennong Rd., Yilan County, Yilan City 260, Taiwan. 4 Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei 10617, Taiwan.

Received: 13 October 2019 Accepted: 20 November 2019 Published online: 03 December 2019

References
Abudabos AM, Alyemeni AH, Dalafal YJ, Khan RJ (2017) Effect of organic acid blend and Bacillus subtilis alone or in combination on growth traits, blood biochemical and antioxidant status in broilers exposed to Salmonella typhimurium challenge during the starter phase. J Appl Anim Res 45:538–542
Alvarez J, Sarradell J, Morrison R, Perez A (2015) Impact of porcine epidemic diarrhea on performance of growing pigs. PLoS ONE 10(3):e0120532. https://doi.org/10.1371/journal.pone.0120532
Chang YC, Kao CF, Chang CY, Jeng CR, Tsai PS, Pang VF, Chiou HY, Peng YJ, Cheng KC, Chang HW (2017) Evaluation and comparison of the pathogenicity and host immune responses induced by a G2b Taiwan porcine epidemic diarrhea virus (Strain Pintung 52) and its highly cell-culture passaged strain in conventional 5-week-old pigs. Viruses. https://doi.org/10.3390/v9050121
Cheng YH, Zhang N, Han JC, Chang CW, Hsiao FSH, Yu YH (2018) Optimization of surfactin production from Bacillus subtilis in fermentation and its effects on Clostridium perfringens-induced necrotic enteritis and growth performance in broilers. J Anim Physiol Anim Nutr 102:1232–1244. https://doi.org/10.1111/jpn.12937
Cheng YH, Su LW, Horng YB, Yu YH (2019) Effects of soybean meal fermented by Lactobacillus species and Clostridium butyricum on growth performance, diarrhea incidence and fecal bacteria in weaning piglets. Anim Sci Anh. https://doi.org/10.2478/as‐aehs‐2019‐0042
Cho WK, Kim H, Choi YJ, Yim NH, Yang HJ, Ma JY (2012) Epimedium koreanum Nakai water extract exhibits antiviral activity against porcine epidemic diarrhea virus in vitro and in vivo. Evid Based Compl Alternat Med 2012:985151. https://doi.org/10.1155/2012/985151
Deping Song QP, Chen Y, Zhou X, Zhang F, Li A, Huang D, Qiong W, Ye Y, He H, Wang L, Tang Y (2017) Altered gut microbiota profiles in sows and neonatal piglets associated with porcine epidemic diarrhea virus infection. Sci Rep. https://doi.org/10.1038/s41598-017-17830-z
Huang X, Lu Z, Zhao H, Bié X, Li F, Yang S (2006) Antiviral activity of antimicrobial lipopeptide from Bacillus subtilis fmbt against pseudorabies virus, porcine parovirus, Newcastle disease virus and infectious bursal disease virus in vitro. Intern J Pest Sci Ther 12(4):373–377. https://doi.org/10.1016/j.ipst.2005.04.001
Hwang YH, Kim MS, Song IB, Park BK, Lim JH, Park SC, Yun H (2009) Subacute (28 day) toxicity of surfactin C, a lipopeptide produced by Bacillus subtilis, in rats. J Health Sci 55(3):351–355
Jung K, Saff LJ (2015) Porcine epidemic diarrhea virus infection: etiology, epidemiology, pathogenesis and immunoprophylaxis. Vet J 204(2):134–143. https://doi.org/10.1016/j.tvjl.2015.02.017
Kim HB, Lee CY, Kim SJ, Han JH, Choi KH (2015) Medicinal herb extracts ameliorated impaired growth performance and intestinal lesion of newborn piglets challenged with the virulent porcine epidemic diarrhea virus. J Anim Sci Technol 57:33. https://doi.org/10.1186/s40781-015-0065-1
Kwon HJ, Ryu YB, Kim YM, Song N, Kim CF, Rho MC, Jeong JH, Cho KO, Lee WS, Park SJ (2013) In vitro antiviral activity of phlorotannins isolated from Ecklonia cava against porcine epidemic diarrhea coronavirus infection and hemagglutination. Bioorg Med Chem 21(15):4706–4713. https://doi.org/10.1016/j.bmc.2013.04.085
Lan R, Kim IH (2019) Effects of Bacillus licheniformis and Bacillus subtilis complex on growth performance and faecal noxious gas emissions in growing-finishing pigs. J Sci Food Agric 99(4):1554–1560. https://doi.org/10.1002/jsfa.9333
Lee C (2015) Porcine epidemic diarrhea virus: an emerging and re-emerging epizootic swine virus. Virol J 12:193. https://doi.org/10.1186/s1298 5-015-0421-2
Lin ER, Cheng YH, Hsiao FSH, Proksura WS, Dybus A, Yu YH (2019) Optimization of solid-state fermentation conditions of Bacillus licheniformis and its effects on Clostridium perfringens-induced necrotic enteritis in broilers. R Bras Zootec. 48:e20170298. https://doi.org/10.1590/rbraz20170298
Reed LJMH (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27:493–497
Schneider AMM (1998) Genetic evidence for a role of thiostrepenoides, integrated in or associated with peptide synthetases, in non-ribosomal peptide biosynthesis in Bacillus subtilis. Arch Microbiol 169(5):404–410
Sen R (2010) Biosurfactants, vol 24. Springer, Berlin
Song JH, Choi HJ (2011) Quercetin 7-rhamnoside reduces porcine epidemic diarrhea virus replication via independent pathway of viral induced reactive oxygen species. Virol J 8:460
Song D, Park B (2012) Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines. Virus Genes 44(2):167–175. https://doi.org/10.1007/s11262-012-0713-1
Torres MJ, Villena JC, Barroso PA, Novicov FM, Audisio MC (2017) Safety assessment of the antimicrobial lipopeptides synthesized by Bacillus subtilis Subsp. subtilis CBMDC3f. EC Microbiol. 8:3
Vollenbroich D, Özel M, Vater J, Kamp RM, Pauli G (1997) Mechanism of inactivation of enveloped viruses by the biosurfactant surfactin from Bacillus subtilis. Biologicales 25(1):289–297

Wang X, Hu W, Zhu L, Yang Q (2017) Bacillus subtilis and surfactin inhibit the transmissible gastroenteritis virus from entering the intestinal epithelial cells. Biosci Rep 37:2. https://doi.org/10.1042/bsr20170082
Youn-Hwan Hwang B-KP, Lim J-H, Kim M-S, Song I-B, Park S-C, Yun H-I (2008) Evaluation of genetic and development toxicity of surfactin C from Bacillus subtilis BC1212. J Health Sci 54(1):101–106

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.